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Background: Studies assessing ischemic mitral regurgitation (IMR) comprised of heterogeneous population and
evaluated IMR in the subacute setting. The incidence of early IMR in the setting of primary PCI, its progression and
clinical impact over time is still undetermined. We sought to determine the predictors and prognosis of early IMR
after primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI).
Methods: Using our primary PCI database, we screened for patients who underwent ≥2 transthoracic
echocardiograms early (1–3 days) and late (1 year) following primary PCI. The primary outcomes were: (1) major
adverse events (MACE) including death, ischemic events, repeat hospitalization, re-vascularization and mitral repair
or replacement (2) changes in quantitative echocardiographic assessments.
Results: From January 2006 to July 2012, we included 174 patients. Post-primary PCI IMR was absent in 95 patients
(55%), mild in 60 (34%), and moderate to severe in 19 (11%). Early after primary PCI, IMR was independently
predicted by an ischemic time > 540 min (OR: 2.92 [95% CI, 1.28 – 7.05]; p = 0.01), and female gender (OR: 3.06
[95% CI, 1.42 – 6.89]; p = 0.004). At a median follow-up of 366 days [34–582 days], IMR was documented in 44% of
the entire cohort, with moderate to severe IMR accounting for 15%. During follow-up, MR regression (change ≥ 1
grade) was seen in 18% of patients. Moderate to severe IMR remained an independent predictor of MACE (HR: 2.58
[95% CI, 1.08 – 5.53]; p = 0.04).
Conclusions: After primary PCI, IMR is a frequent finding. Regression of early IMR during long-term follow-up is
uncommon. Since moderate to severe IMR post-primary PCI appears to be correlated with worse outcomes, close
follow-up is required.
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Myocardial infarctionIntroduction
Functional ischemic mitral regurgitation (IMR) has been
described after acute myocardial infarction (MI). However,
its prevalence and spectrum of severity has constantly var-
ied in previously published studies (1–18). This disparity is
explained by the different methods utilized for assessing
IMR, the heterogeneity of studied populations, and* Correspondence: mario.senechal@criucpq.ulaval.ca
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article, unless otherwise stated.different reperfusion utilized techniques [1-18]. In addition,
some of this data is based on secondary analysis of clinical
trials [1,9,10,12,13], which are subject to referral and
selection biases, while others assessed and quantified the
severity of IMR in the subacute time period [2-6,16,17].
Finally, of these studies, only a minority was based on
modern primary PCI strategy [3,9,15,18].
The presence of IMR is clinically relevant as it has been
associated with poorer clinical outcomes [6,10,13] and can
lead to a worse prognosis in patients undergoing coronary
artery bypass grafting (CABG) [19]. Primary PCI has be-
come the preferred method for reperfusion therapy inntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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remodeling, lowers complication rates and improves sur-
vival [20-22]. Some recent data has also suggested that pri-
mary PCI could decrease the incidence of IMR after
STEMI [3].
Our study primary aim was to address the aforemen-
tioned gaps by determining the predictors of early IMR,
and to evaluate the prognostic value of IMR after pri-
mary PCI. Additionally, we sought to evaluate the preva-
lence and severity of early IMR in the acute phase of
STEMI treated with primary PCI and to assess the echo-
cardiographic changes in quantitative IMR over one
year.Methods
Patient population and follow-up
From January 2006 to July 2012, 174 consecutive pa-
tients who were referred to our tertiary care university
center for primary PCI within 12 h after symptom onset,
who underwent early (1–3 days) and late echocardio-
graphic studies, and had appropriate clinical follow-up
at our center we retrospectively included. Exclusion
criteria were: 1) previous CABG, 2) STEMI patients
without any significant coronary lesion or in whom
recent fibrinolytic therapy was administered, 3) patients
with any valvular pathology other than MR or mitral
valve papillary muscle rupture and 4) patients with in-
complete echocardiographic data. Cardiac catheterization
was performed via radial approach using 5–6 Fr-
guiding catheters, with every patient receiving aspirin
and clopidogrel. Adjunctive pharmacotherapy, such as
bivalirudin or glycoprotein IIb/IIIa inhibitors was left
to the operator’s discretion and was similar between all
groups. All patients gave informed written consent.
This study was performed in accordance with our insti-
tution review board and ethics committee. This study
is conform to ethical committee rules of Institut uni-
versitaire de cardiologie et de pneumologie de Québec,
Québec, Canada.
IMR was classified from analysis of clinical informa-
tion, operative reports, and echocardiograms. MR was
judged to be ischemic in origin when the valve leaflets
and chordae were normal and the regurgiation was
caused as a consequence of the STEMI. For analysis, pa-
tients were stratified according to their baseline IMR
after primary PCI. Baseline data was obtained from a
computerized medical database of prospectively re-
corded demographic, clinical and procedural informa-
tion. Clinical follow-up information was obtained from
the referring physicians or via direct phone contact with
patients. Finally, information on vital status at 1 year
was also collected from the Quebec death registry
“Directeur de l’État Civil” Quebec service counter.Echocardiographic analysis
Two-dimensional and Doppler transthoracic echocardi-
ography examinations were performed using Philips
Medical Systems (Amsterdam, Netherlands) platforms.
The two-dimensional echocardiograms were analyzed
by two experienced investigators (J.M. and M.S.)
via the Xcelera Echo Lab Management (Amsterdam,
Netherlands). The inter-observer reliability, based on the
interclass correlation coefficient, for all echocardio-
graphic data were very good with absolute values higher
than 0.87.
All patients had early post-PCI (1–3 days) (Echo 1),
and long-term follow-up (median: 244 days [85 –
533 days] (Echo 2)) echocardiographic studies. Left
ventricular ejection fractions (LVEF) and volumes were
averaged values from the apical 4-chamber and 2-
chamber views and calculated using the modified bi-
plane Simpson method. LV dimensions were measured
using M-mode technique via the parasternal-long axis
view. LV sphericity index was calculated by dividing the
LV short-axis dimension by the LV long-axis dimension
in the 4-chamber view. Left atrial (LA) size was assessed
by averaging the LA volume measured in 4-chamber and
2-chamber views with the use of 2-dimensional planim-
etry [23]. Pulmonary artery pressure (PASP) was calcu-
lated as per recommendations. Mitral regurgitation was
quantified initially using color flow Doppler, adding
supportive signs and quantitative parameters (predomin-
antly vena contracta (VC)) and according to the American
Society of Echocardiography guidelines [24]. In cases of
discrepancy between the methods as to the grade of
MR, the available quantitative parameter was used as
the reference technique.
Outcomes
Procedural success was defined as a final Thrombolysis
In Myocardial Infarction flow of 3 with a residual sten-
osis of <20%. Death was defined as all-cause mortality.
Re-hospitalization was defined as hospital admissions for
acute heart failure. Myocardial infarction definition was
based on the previously published universal definition of
myocardial infarction [25]. The rate of major adverse
cardiac events (MACE) was the composite of death, MI,
stroke, re-hospitalization for congestive heart failure,
PCI or CABG and mitral repair or replacement.
Statistical analysis
Categorical variables were expressed as numbers and
percentages and continuous variables as mean ± SD or
medians with interquartile range [IQR]. Differences
between groups were assessed using ANOVA for con-
tinuous variables, and the Pearson’s χ2 test test for
categorical variables as appropriate. The Cox propor-
tional hazard model was used to identify independent
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verity and MACE were chosen from patient’s baseline
clinical, procedural and echocardiographic character-
istics. IMR grade was chosen as a categorical value.
Variables were selected with stepwise, backward, and
forward procedures with logistic regression analyses,
which were entered into the model at p < 0.10 and
retained at p < 0.05. The cutoff values relating to base-
line LVESD, and ischemic time prior to revascularization
procedure were based on ROC curve analysis. Survival
curves were constructed using Kaplan-Meier methods
with comparisons made using the log-rank test. A prob-
ability value of < 0.05 was considered significant and all
calculations and statistical tests were performed using
JMP statistical software version 10.0.0 (SAS institute,
Cary, NC).
Results
Clinical follow-up was complete in all patients. Overall
mean age was 63 ± 12 years. Majority of the 174 patients
(79%) were males and clinical median follow-up was
366 days [IQR: 34 – 582 days]. Patients with moderate
to severe IMR involved more patients aged > 65 years
(p = 0.046) and more women (p = 0.006) (Table 1). There
was also a progressive increase in ischemic time prior to
PCI according to MR severity (297 ± 23 min for no MR
vs. 301 ± 28 min for mild MR vs. 486 ± 52 min forTable 1 Baseline characteristics
Variable ALL (n = 174; 100%) No MR (n = 95;
Age (yrs) 63 ± 12 61 ± 1
Age > 65 73 (42%) 37 (39%)
Male sex 138 (79%) 83 (87%)
Weight (kg) 82 ± 56 86 ± 6
Height (cm) 170 ± 8 171 ± 1
Body mass index (kg/m2) 28 ± 21 30 ± 2
Body surface area (m2) 1.94 ± 0.37 1.96 ± 0.03
Diabetes mellitus 19 (11%) 9 (10%)
Hypertension 83 (48%) 41 (43%)
Current smoking 64 (37%) 41 (43%)
Dyslipidemia 81 (47%) 38 (40%)
Stable angina 12 (7%) 4 (4%)
Unstable angina 4 (2%) 2 (2%)
Prior MI 17 (10%) 9 (10%)
Prior PCI 13 (9%) 4 (4%)
Creatinine clearance (mL/min)† 84 ± 49 89 ± 5
GFR > 60 mL/min 128 (78%) 73 (83%)
Follow-up (days) 366 [34–582] 476 ± 42
†Based on the the Cockroft-Gault equation.
MR: Mitral Regurgitation; MI - Myocardial infarction; PCI - Percutaneous interventionmoderate or severe MR; p = 0.004) (Table 2). Angio-
graphic parameters prior and after primary PCI were
similar between groups.
Echocardiographic characteristics
Early after primary PCI, IMR was absent in 95 patients
(55%), mild in 60 (34%), moderate or severe in 19 (11%).
Left-ventricular systolic dimension (LVESD) increased in
a graded relationship with aggravation of IMR (3.4 cm ±
0.1 vs. 3.6 cm ± 0.1 vs. 3.8 cm ± 0.1; p = 0.02), translating
into lower LVEF (48% ± 1 vs. 45% ± 2 vs. 41% ± 3; p =
0.03) (Table 3).
The echocardiographic studies median follow-up was
244 days [85 – 533 days], with the moderate to severe
IMR incidence accounting for 15%. No differences be-
tween groups were observed at the end of follow-up
with respect to diastolic and systolic echocardiographic
parameters. A lower LVEF was observed as the severity
of IMR increased (53% ± 1 for no MR vs. 52% ± 2 for
mild MR vs. 44% ± 3 for moderate or severe MR; p =
0.02), with the left ventricular sphericity increasing sig-
nificantly over time only in the moderate to severe MR
group (Table 3). IMR progressed or regressed (by ≥ 1
grade) in 38 (22%) and 32 (18%) patients, respectively.
Analysis of patient’s according to their baseline MR
grade is presented in Figure 1. Seven percent of patients
(n = 11) with clinically no or mild IMR progressed to a55%) Mild MR (n = 60; 34%) Moderate or severe MR
(n = 19; 11%)
P value
63 ± 2 66 ± 3 0.21
23 (38%) 13 (68%) 0.046
44 (73%) 11 (58%) 0.006
78 ± 7 78 ± 13 0.43
170 ± 1 166 ± 2 0.08
27 ± 3 28 ± 5 0.33
1.91 ± 0.05 1.90 ± 0.09 0.57
7 (12%) 3 (16%) 0.70
31 (52%) 11 (58%) 0.38
21 (35%) 2 (11%) 0.03
32 (53%) 11 (58%) 0.15
5 (8%) 3 (16%) 0.17
1 (2%) 1 (5%) 0.65
5 (8%) 3 (16%) 0.63
6 (10%) 3 (16%) 0.18
79 ± 7 72 ± 11 0.30
40 (69%) 15 (79%) 0.14
455 ± 52 364 ± 93 0.49
; eGFR - Estimated glomerular filtration rate.
Table 2 Angiographic characteristics
Variable ALL (n = 174; 100%) No MR (n = 95; 55%) Mild MR (n = 60; 34%) Moderate or severe MR
(n = 19; 11%)
P value
Ischemic time (min)* 319 ± 226 297 ± 23 301 ± 28 486 ± 52 0.004
Thrombectomy catheter 104 (60%) 59 (62%) 35 (59%) 10 (53%) 0.73
Multi-vessel disease¶ 88 (52%) 43 (45%) 34 (57%) 13 (68%) 0.12
Culprit vessel
Left anterior descending 83 (48%) 49 (52%) 28 (47%) 6 (32%) 0.28
Left circumflex 27 (16%) 14 (15%) 9 (15%) 4 (21%) 0.78
Right coronary artery 63 (36%) 32 (34%) 22 (37%) 9 (47%) 0.52
TIMI Flow – pre-stenting
0 73 (42%) 38 (40%) 26 (43%) 9 (47%) 0.81
1 73 (42%) 39 (41%) 27 (45%) 7 (37%) 0.79
2 11 (6%) 8 (8%) 2 (3%) 1 (5%) 0.44
3 17 (10%) 9 (10%) 6 (10%) 2 (11%) 0.99
0 or 1 146 (84%) 77 (81%) 53 (88%) 16 (84%) 0.49
TIMI Flow – post- stenting
0 1 (1%) 0 (0%) 1 (2%) 0 (0%) 0.39
1 3 (2%) 0 (0%) 3 (5%) 0 (0%) 0.06
2 26 (15%) 16 (17%) 7 (12%) 3 (16%) 0.68
3 143 (83%) 79 (83%) 49 (82%) 16 (84%) 0.96
0 or 1 4 (2%) 0 (0%) 4 (7%) 0 (0%) 0.02
Angiographic success† 149 (86%) 82 (86%) 50 (83%) 17 (90%) 0.77
Peak CK-MB (μg/L) (ug/L) 173.4 [56.0 – 378.8] 151 [56–365] 212 [77 – 373] 163 [6.9 – 481] 0.66
Peak troponin T (μg/L) 4.7 [2.2 – 8.9] 4.5 [2.4 – 7.9] 5.1 [2.2 – 9.1] 5.9 [1.7 – 11.4] 0.45
*Ischemic time: defined as the time difference between beginning of the chest pain and artery opening.
¶Multivessel disease: defined as significant coronary artery disease (>50% diameter stenosis) in ≥ 2 major epicardial artery.
†Angiographic success: defined as <20% residual stenosis + TIMI 3 flow post-PCI.
MR: Mitral Regurgitation; TIMI - Thrombolysis in myocardial infarction; CK-MB - Serum myocardial band of creatine kinase.
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from moderate or severe to no or mild grade.
Clinical outcomes
No difference was observed in early (≤ 30 days) mortal-
ity (0% vs. 2% vs. 0%; p = 0.39) and CABG revasculariza-
tion (2% vs. 0% vs. 5%; p = 0.28) between all 3 groups.
The composite MACE endpoint was observed more fre-
quently within the moderate or severe group (16% vs.
17% vs. 42%; p = 0.02) (Table 4 and Figure 2). This was
mainly driven by a higher number of surgical revascular-
ization procedures (CABG - no-MR: 6% vs. mild MR:
7% vs. moderate or severe MR: 26%; p = 0.008) with con-
comitant mitral valve intervention (no-MR: 0% vs. mild
MR: 0% vs. moderate or severe MR: 26%; p < 0.0001).
From the multivariate analysis, we found that IMR
early after primary PCI was independently predicted by
an ischemic time prior to PCI > 540 min (OR: 2.92 [95%
CI, 1.28 – 7.05]; p = 0.01), and female gender (OR: 3.06
[95% CI, 1.42 – 6.89]; p = 0.004). Furthermore, moderate
to severe MR was a strong independent predictor of 1-year MACE (HR: 2.58 [95% CI, 1.08 – 5.53]; p = 0.04).
Other independent predictors of 1-year MACE included
multivessel disease (HR: 3.09 [95% CI, 1.47 – 7.13];
p = 0.003) and LVESD at baseline ≥ 40 mm (HR: 2.13
[95% CI, 1.00 – 4.30]; p = 0.05) (Figure 3).
Discussion
After primary PCI for acute STEMI within 12 hours of
symptom onset, we found that: 1) moderate to severe
IMR by quantitative echocardiographic analysis is appar-
ent in 11% of patients acutely and remains evident in
15% after a median follow-up of 1 year; 2) female gender,
and longer ischemic time are strong independent predic-
tors of early significant IMR; 3) IMR could worsen in pa-
tients with evidence of none or mild IMR at baseline
and usually will not regress in those with significant MR;
4) the presence of moderate or severe IMR, multivessel
disease or an LVESD at baseline ≥ 40 mm predict pa-
tients worse late clinical outcomes; 4) Importantly, pa-
tients with moderate to severe IMR experience a higher
incidence of one year MACE, which is mainly driven by
Table 3 Echocardiographic characteristics at baseline and follow-up
Variable ALL (n = 174; 100%) No MR (n = 95; 55%) Mild MR (n = 60; 34%) Moderate or severe MR
(n = 19; 11%)
P value
Baseline (POST-PCI)
LVEDD (mm) 47 ± 6 46 ± 1 47 ± 1 48 ± 1 0.40
LVESD (mm) 35 ± 7 34 ± 1 36 ± 1 38 ± 2 0.02
LVESD >40 mm 39 (22%) 15 (16%) 18 (30%) 6 (32%) 0.07
LVEDV (ml) 102 ± 35 100 ± 4 104 ± 5 107 ± 8 0.68
LVESV (ml) 57 ± 29 53 ± 3 59 ± 4 66 ± 7 0.16
LVEF (%) 46 ± 12 48 ± 1* 45 ± 2* 41 ± 3 0.03
LV sphericity – diastole (%) 0.55 ± 0.07 0.54 ± 0.01 0.56 ± 0.01 0.56 ± 0.02* 0.29
LA volume - indexed (ml/m2) 26 ± 9 23 ± 1* 28 ± 1 36 ± 2 <0.0001
MR – Vena Contracta (cm) 0 [0 – 0.23] 0 [0 – 0]* 0.19 [0.10 – 0.27] 0.62 [0.53 – 0.7]* <0.0001
PASP (mmHg) 29 ± 10 26 ± 1 29 ± 1 43 ± 3 <0.0001
Long-term follow-up
LVEDD (mm) 48 ± 9 48 ± 1 48 ± 1 51 ± 2 0.34
LVESD (mm) 35 ± 10 34 ± 1 35 ± 1 39 ± 2 0.11
LVEDV (ml) 114 ± 47 111 ± 5 116 ± 6 120 ± 10 0.71
LVESV (ml) 59 ± 40 56 ± 4 60 ± 5 72 ± 9 0.27
LVEF (%) 52 ± 13 53 ± 1* 52 ± 2* 44 ± 3 0.02
LV sphericity – diastole (%) 0.57 ± 0.09 0.55 ± 0.01 0.57 ± 0.01 0.61 ± 0.02* 0.01
LA size - indexed (ml/m2) 30 ± 12 27 ± 1* 30 ± 2 41 ± 3 <0.0001
MR – Vena Contracta (cm) 0.1 [0 – 0.23] 0 [0 – 0.19]* 0.12 [0 – 0.24] 0.54 [0.44 – 0.6]* <0.0001
PASP (mmHg) 28 ± 10 26 ± 1 27 ± 1 36 ± 2 0.001
*Difference between baseline and long-term follow-up values is statistically significant; (all p-values ≤ 0.03).
LVEDD – Left ventricular end-diastolic diameter; LVESD – Left ventricular end-systolic diameter; LVEDV – Left ventricular end-diastolic volume; LVESV – Left
ventricular end-systolic volume; LVEF – Left Ventricular Ejection Fraction; LA – Left atrium; MR- Mitral regurgitation; PASP – Pulmonary artery systolic pressure.
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with concurrent valvular correction.
Functional IMR has an important prognostic impact
after myocardial infarction. It is generated by papillary
muscles displacement secondary to the infarcted LVFigure 1 Distribution of ischemic functional mitral regurgitation (MR)[26]. Due to the non-extensibility of the chordae, pa-
pillary muscle translation exerts traction on leaflets
through strut chordae implanted on the leaflets body
[27,28]. This produces tethering with apical and lateral
leaflets displacement [26,29], annular flattening andover time according to baseline MR grade.
Table 4 Cumulative clinical outcomes according to early ischemic MR severity
Variable All (n = 174; 100%) No MR (n = 95; 55%) Mild MR (n = 60; 34%) Moderate or severe MR
(n = 19; 11%)
P value
Death 2 (1%) 0 (0%) 1 (2%) 1 (5%) 0.13
Stroke 3 (2%) 2 (2%) 1 (2%) 0 (0%) 0.81
Re-infarction 13 (8%) 10 (11%) 2 (3%) 1 (5%) 0.23
Re-Hospitalization for CHF 2 (1%) 0 (0%) 1 (2%) 1 (5%) 0.13
Percutaneous coronary intervention 9 (5%) 6 (6%) 2 (3%) 1 (5%) 0.72
Coronary artery bypass grafting 14 (8%) 5 (6%) 4 (7%) 5 (26%) 0.008
Annuloplasty or mitral valve surgery 5 (3%) 0 (0%) 0 (0%) 5 (26%) <0.0001
MACE* 33 (19%) 15 (16%) 10 (17%) 8 (42%) 0.02
*Major adverse cardiac events (MACE): defined as a combined endpoint of death, MI, stroke, re-hospitalization for congestive heart failure, PCI or CABG and mitral
repair or replacement.
MR: Mitral Regurgitation; CHF: Congestive Heart Failure; MACE: Major Adverse Cardiovascular Event.
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tional IMR. The prevalence has been variable (Table 5)
as it is dependent on the detection technique utilized. It
ranges from <20% in angiographic studies [10-14] to as
high as 60% in echocardiographic studies [1-8,15,30-33],
with moderate or severe IMR accounting for <5% and
10-15% of cases, respectively. This discrepancy reflects
the selection biases inherent to most studies, as most in-
volved a heterogeneous sample size that included a mix-
ture of STEMI and NSTEMI patients. Some were
exposed to selection bias as they were based on sub-
analysis of larger randomized trials [1,10,12,13] while
others were samples of patients admitted to the coronary
care unit. Furthermore, various studies were solely based
on thrombolytic therapy [1,10,12-14,32,33], which is rec-
ognized as a less effective treatment in STEMIs vs. pri-
mary PCI [34], and ultimately not everyone excludedFigure 2 Kaplan-Meier curves for the combined endpoint of MACE (d
PCI or CABG and mitral repair or replacement).patients with previous MI [2-4,32]. Our study attempted
to take into consideration most of these issues by select-
ing a homogenous sample population composed of all-
comers presenting to the catheterization laboratory in
the setting of primary PCI setting, and in the first
12 hours of symptoms onset. Additionally, these patients
were all treated within today’s standard of care.
In accordance to previous studies [1,7,9,13,30], our data
indicate that female gender is an important determinant in
the severity of early IMR. This finding may partly provide
an explanation for the higher incidence of post-STEMI
mortality seen in females [35-37]. We have also found that
longer ischemic time prior to PCI is an important deter-
minant in the severity of IMR. This finding once again em-
phasizes the notion of early opening of the infarcted-artery
with the aim of salvaging as much muscle mass as possible;
therefore reducing the rate of IMR occurrence.eath, MI, stroke, re-hospitalization for congestive heart failure,
Figure 3 Independent predictors for the combined endpoint of MACE (death, MI, stroke, re-hospitalization for congestive heart failure,
PCI or CABG and mitral repair or replacement).
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pendent predictor of outcome as it doubled mortality
rates and increased the incidence of hospital admis-
sions for heart failure [1,6,10,13]. Our data does not
suggest large differences in the individual clinical
outcomes between all 3 groups. We hypothesize that
this difference results specifically from the different
timeline in which these studies occurred (early 1980s
to late 1990s vs. late 2000s to early 2010s). During this
time period, percutaneous approaches and pharmacologic
treatments have significantly improved, thus enhancing
clinical outcomes. Nonetheless, MACE outcome was
higher in the moderate to severe MR group and was
mainly driven by surgical coronary revascularization
and mitral valve surgical correction >30 days after the
index ischemic event. Interestingly, all patients in the
moderate to severe MR group who underwent surgical
revascularization required mitral surgical correction.
This indicates that this group of patients necessitate
close follow-up in the first year post-PCI, as in the
majority of cases, the moderate to severe MR will not
regress, leading to an indication for surgical interven-
tion. Lastly, the presence of moderate to severe MR,
multi-vessel coronary artery disease and a large ven-
tricular dimension predicted the development of
MACE, all of which are indicative of a higher risk
population.
The ACC/AHA and ESC/EACTS guidelines [38,39]
provide little and unclear recommendations as for
surgical treatment in functional IMR. The only echo-
cardiographic parameter used to guide clinicians is anLVEF ≥ 30% in patients with moderate to severe IMR
undergoing CABG that was recently adopted in the
ESC/EACTS guidelines [39]. Our data suggest that,
similar to degenerative MR, an increase in LVESD (≥
40 mm) may also be an appropriate clinical marker
for poor long-term clinical outcome. Future prospect-
ive trials are clearly required to definitely answer this
question.Limitations
The primary limitation of this study lies in the ret-
rospective nature of data collection. The inherent
treatment biases of the physicians caring for the pa-
tients could have lead to the introduction of selec-
tion bias or unidentified confounding factors that
may have influenced our results. Our facility is a ter-
tiary care center that accepts patients from different
centers for the primary PCI procedure, and returned
to the original center as soon as hemostasis is
achieved. This approach might have underestimated
the true value of IMR. Our echocardiographic data
is observed after the MI and do not exclude that
some MR was present beforehand in some patients,
a limitation shared by most studies on this topic.
Nonetheless, our prevalence exceeds what has been
documented in the general population [40] therefore;
it is most likely attributed to the MI. A prospec-
tive multicenter study evaluating LV remodeling and
powered for clinical outcomes should be performed
to validate our results.







Treatment strategy STEMI F/U Death (%) Other Mitral surgical
correction (%)
Barzilai et al. [31]
(1985-1986)
59 39 NR NR 59% 14 m MR (+): 48%, MR (0):
11%
NR NR
Bursi et al. [2]
(1988-1998)
773 50 12 NR 59% 5 y None: 28%, Mild: 38%,
M-S: 60%
CHF Adm NR
None: 16%, Mild: 26%,
M-S: 65%
Grigioni et al. [6]
(1990-1997)





Amigoni et al. (Valiant
study) [1]
(1998-2001)
496 53 13 Thrombolytic (40%),
PCI (19%)
63% 20 m None: 10%, Mild: 21%,
M-S: 30%
NR NR
Feinberg et al. [5]
(1996)
417 35 6 Thrombolytic (42%),
PTCA / CABG (41%)
100% 1 y None: 4.8%, Mild: 12.4%,
M-S: 24%
NR NR
Van Dantzig et al. [33]
(1991-1993)
188 NR 13 Thrombolytic (55%) 62% NR NR NR NR
Leor et al. [32] (N/A) 104 33 11 Thrombolytic (100%) 100% 1 m NR NR NR
Aronson et al. [30]
(2000-2005)
1190 46 6 PCI (30%) 100% 2 y None: 8%, Mild: 15%,
M-S: 38%
CHF Adm NR
None: 0.6%, Mild: 3.6%,
M-S: 4%
Barra et al. [16]
(2006-2008)
796 45 15 PCI (56%) 45% 2 y None: 12%, Mild: 22%,
M-S: 39%
CHF Adm NR
None: 11%, Mild: 24%,
M-S: 20%
Chung et al. [4]
(2000-2002)
519 56 15 PCI (81%) 86% 6 m None - Mild: 10%,
M-S: 19%
NR NR
Chua et al. [3]
(2000-2004)
318 17 NR PCI (100%) 100% 7 y MR (+): 49%,
MR (0): 26%
NR NR
Wita et al. [15] (N/A) 83 42 NR PCI (100%) 100% 6 m NR NR NR
Uddin et al. [18]
(2003-2007)
888 47 11 PCI (100%) 100% 5 y None: 13%, Mild: 18%,
M-S: 34%




174 44 11 PCI (100%) 100% 1 y None: 0%, Mild: 2%,
M-S: 5%
CHF Adm None: 0%, Mild: 0%,
M-S: 26%
None: 0%, Mild: 2%,
M-S: 5%
MR: Mitral Regurgitation; STEMI: ST elevation Myocardial Infarction; F/U: follow-up; PTCA: Percutaneous transluminal coronary angioplasty; PCI: Percutaneous Coronary Intervention; CABG: Coronary Artery Bypass


















MacHaalany et al. Cardiovascular Ultrasound 2014, 12:14 Page 9 of 10
http://www.cardiovascularultrasound.com/content/12/1/14Conclusions
In the era of primary PCI for STEMI, early and 1-year
post-PCI moderate to severe IMR was documented in
11% and 15% respectively. Female gender, and ischemic
time prior to PCI > 540 min strongly predicted the oc-
currence of IMR while multivessel disease, moderate or
severe MR, and LVESD at baseline ≥ 40 mm predicted
combined MACE outcome. Moreover, around 25% of
patients with moderate to severe IMR required sub-
sequent surgical revascularization with mitral valve
surgical correction. Close clinical follow-up is highly
recommended in this particular population as indica-
tion for surgical intervention may likely arise in the
first year post-ischemic event.
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